---
title: "Top Executive Quietly Ramps Up Stake in This Under-the-Radar Biotech"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296865766.md"
description: "Protagenic Therapeutics executive Garo Armen purchased 20,000 shares worth $13,000 on August 24, 2026, signaling confidence. The stock is influenced by positive FDA feedback on its PT00114 pre-IND package for generalized anxiety disorder and a late Form 10-Q filing, which raises governance uncertainty. Despite the insider buy, the stock has fallen 38.38% year-to-date with a 'Sell' technical sentiment."
datetime: "2026-08-25T02:10:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296865766.md)
  - [en](https://longbridge.com/en/news/296865766.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296865766.md)
generator: "portal-rs"
---

# Top Executive Quietly Ramps Up Stake in This Under-the-Radar Biotech

New insider activity at Protagenic Therapeutics ( (PTIX) ) has taken place on August 24, 2026.

Executive Chair and Principal Officer Garo Armen has boosted his stake in Protagenic Therapeutics by purchasing 20,000 shares of the company’s stock, in a transaction valued at $13,000, signaling a notable vote of confidence from the firm’s leadership.

In the past day, Protagenic Therapeutics’ stock activity has been driven by two contrasting developments: supportive FDA feedback on its pre-IND package for PT00114 in generalized anxiety disorder, and a notification that its latest Form 10-Q will be filed late. The FDA’s endorsement of the planned Phase 1 design and CMC strategy improves clinical visibility, while the extended reporting delay heightens uncertainty around governance and financial execution, tempering sentiment despite no expected major earnings surprise.

**More about Protagenic Therapeutics**

**YTD Price Performance:** -38.38%

**Average Trading Volume:** 14,188

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $1.45M

### Related Stocks

- [PTIX.US](https://longbridge.com/en/quote/PTIX.US.md)
- [PTIXW.US](https://longbridge.com/en/quote/PTIXW.US.md)

## Related News & Research

- [Protagenic gets FDA pre-IND feedback supporting planned Phase 1 trial for PT00114 in generalized anxiety disorder](https://longbridge.com/en/news/296491293.md)
- [Definium Therapeutics to present Phase 3 topline data for DT120 in MDD, GAD at Psych Congress 2026](https://longbridge.com/en/news/298582158.md)
- [VistaGen reports Phase 3 fasedienol shows positive efficacy signal in severe social anxiety subgroup analysis](https://longbridge.com/en/news/298595046.md)
- [Concurrent Investment Advisors LLC Acquires 6,576 Shares of Alnylam Pharmaceuticals, Inc. $ALNY](https://longbridge.com/en/news/298418429.md)
- [Definium Therapeutics’ DT120 LSD tablet wins FDA breakthrough tag in major depressive disorder after Phase 3 study](https://longbridge.com/en/news/298306740.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**